MUMBAI, India, Sept. 28 -- Intellectual Property India has published a patent application (202631112079 A) filed by Mr. Rajeswar Das; Dr. Durga Prasad Kemisetti; Dr. Bolay Bhattacharya; Dr. Saikat Sen; Dr. Faruk Alam; Dr. Kumara Swamy Samanthula; Dr. Subas Chandra Dinda; Dr. Mohidul Islam; Hiyashree Sharmah; and Prasurjya Saikia on September 18, 2026, for A Standardized Hydroethanolic Extract Of Musa Paradisiaca Spathe For Hematological And Regenerative Applications.
Inventors include Mr. Rajeswar Das; Dr. Durga Prasad Kemisetti; Dr. Bolay Bhattacharya; Dr. Saikat Sen; Dr. Faruk Alam; Dr. Kumara Swamy Samanthula; Dr. Subas Chandra Dinda; Dr. Mohidul Islam; Hiyashree Sharmah; and Prasurjya Saikia.
The application for the patent was published on September 25, 2026, under issue no. 39/2026.
Abstract: The present invention relates to a hydroethanolic extract of Musa paradisiaca spathe (HAE-MP) and its pharmaceutical and nutraceutical applications. The extract is prepared by ultrasonic-assisted extraction using ethanol-water (50:50 v/v) and exhibits the highest extraction yield (21.11%), greatest iron content (883.18 mg/kg), and most diverse phytochemical profile among tested solvent systems. GC-MS analysis reveals oxygenated hydrocarbons, nitrogen-containing heterocycles, and steroidal compounds. The extract demonstrates significant wound healing activity and anti-inflammatory effects through downregulation of IL-6 and TNF-alpha with concurrent IL-10 restoration. Safety is confirmed through OECD Guidelines 423 and 407 with no treatment-related toxicity. In a phenylhydrazine-induced anemia model, oral HAE-MP (500 mg/kg) significantly improves erythrocyte count, hemoglobin, hematocrit, serum iron, ferritin, and transferrin saturation while reducing oxidative stress markers. The invention provides a safe, sustainable botanical composition for iron deficiency anemia management.
Disclaimer: Curated by HT Syndication.
